Longeveron receives committee approval to complete stem cell trial
Tweet Send to a Friend
Longeveron Inc. (NASDAQ: LGVN) announced that an independent Data Monitoring Committee has completed its final review of the company's Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


